Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial
- 1 March 1999
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 353 (9157) , 947-954
- https://doi.org/10.1016/s0140-6736(98)06532-5
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteersGene Therapy, 1997
- CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract.Journal of Clinical Investigation, 1997
- Aerosol Administration of a Recombinant Adenovirus Expressing CFTR to Cystic Fibrosis Patients: A Phase I Clinical TrialHuman Gene Therapy, 1997
- Cystic Fibrosis Airway Epithelia Fail to Kill Bacteria Because of Abnormal Airway Surface FluidCell, 1996
- In Vitro Assessment of Variables Affecting the Efficiency and Efficacy of Adenovirus-Mediated Gene Transfer to Cystic Fibrosis Airway EpitheliaHuman Gene Therapy, 1996
- Cystic fibrosis mutation analysis: Report from 22 U.K. regional genetics laboratoriesHuman Mutation, 1995
- Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosisPublished by Elsevier ,1993
- Cystic fibrosis: current survival and population estimates to the year 2000.Thorax, 1991
- Pathophysiology of Pulmonary Disease in Cystic FibrosisSeminars in Respiratory and Critical Care Medicine, 1985
- Increased Bioelectric Potential Difference across Respiratory Epithelia in Cystic FibrosisNew England Journal of Medicine, 1981